rectal cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. histologically proven malignant tumor of rectal; stage II-III (exclude T4) received transanal total mesorectal excision; 2. Life expectancy 3 months or longer; 3. KPS score =70; 4. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 7 days prior to randomization: Hemoglobin = 100g/L, ANC = 1.5*10^9/L without granulocyte colony-stimulating factor support, Platelet count =100*10^9/L; Serum bilirubin = 1.5×ULN, AST, ALT = 1.5×ULN; Serum creatinine = 1.5 × ULN or eGFR =60ml/min, urea nitrogen =200mg/L; 5. Women who are not postmenopausal or surgically sterile must have a negative serum pregnancy test result within 7 days prior to initiation of study. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception and to continue its use for 180 days after the last radiation; 6. Signed Informed Consent Form; 7. Comply with research plan and follow-up process; 8. Male or female aged 18 to 75 years.
Exclusion criteria
Exclusion criteria: 1. Recurrent patients of rectal carcinoma; 2. Received neoadjuvant radiotherapy for rectal carcinoma; 3. Treatment with any other investigational agent or participation in another clinical trial; 4. Malignancies other than rectal carcinoma within 5 years; 5. History of any systemic diseases including: active infections, uncontrolled hypertension, congestive heart-failure, myocardial infarction, severe arrhythmia, liver, kidney or metabolic diseases; 6. Positive test for HIV; 7. Any other condition that contraindicates the use of radiation or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| toxicity;quality of life;recurrence free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-Free-Survival; | — |
Contacts
Department of oncology Second Affiliated Hospital of Army Medical University